Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer

Basit Öğe Kaydı
dc.authorid0000-0002-0893-1251
dc.authorid0000-0003-4417-4005
dc.authorid0000-0001-7923-275X
dc.authorid0000-0003-4579-7087
dc.authorid0000-0002-2271-8481
dc.authorid0000-0001-6530-0942
dc.authorid0000-0002-8919-0482
dc.authorid0000-0001-8023-3223
dc.contributor.authorŞükrüoğlu Erdoğan, Özge
dc.contributor.authorKılıç Erciyas, Seda
dc.contributor.authorÇelik Demirbaş, Betül
dc.contributor.authorDinç, Ahmet
dc.contributor.authorÜnal, Elif
dc.contributor.authorGüngör Uğurlucan, Funda
dc.contributor.authorAkdeniz Ödemiş, Demet
dc.contributor.authorPasin, Özge
dc.contributor.authorSaip, Pınar Mualla
dc.contributor.authorYazıcı, Hülya
dc.contributor.authorTuncer, Şeref Buğra
dc.date.accessioned2026-08-21T13:46:24Z
dc.date.available2026-08-21T13:46:24Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalı
dc.description.abstractBackground: Ovarian cancer (OC) remains one of the leading causes of gynecological cancer-related mortality, with limited biomarkers for early detection and prognosis. Changes in DNA methylation-stable and detectable in blood-are potential candidates for clinical application. In our earlier genome-wide methylation study involving monozygotic twins where one had ovarian cancer and the other did not, we identified two genes, RBBP7 and RIBC1, as differentially methylated. These findings laid the groundwork for further targeted investigation. Methods and results: Peripheral blood methylation of RBBP7 and RIBC1 was evaluated in 387 ovarian cancer patients, 50 benign ovarian disease patients, and 100 healthy controls using a bisulfite-free, methylation-sensitive restriction enzyme (MSRE)-based qPCR assay. In this approach, DNA is divided into digested and undigested reactions, and methylation levels are calculated from Ct differences. Methylation levels differed across groups, with RBBP7 showing a clearer discriminatory pattern (p < 0.001) and associations with disease severity (p < 0.001) and CA125 levels (p = 0.05). RIBC1 also differed between ovarian cancer and healthy controls (p < 0.001) but showed no significant associations with clinicopathological parameters. Conclusion: RBBP7 methylation appears to be a potential candidate biomarker associated with disease characteristics and progression patterns of ovarian cancer. These findings suggest that RBBP7 methylation may have potential for integration into future multi-marker diagnostic and risk-stratification approaches, pending further validation. While RIBC1 methylation also showed differential patterns, its clinical relevance appears limited and requires further investigation. These findings support the integration of RBBP7 methylation assessment into early-stage diagnostic workflows and risk-stratification strategies for ovarian cancer, enabling more precise clinical decision-making. Future multicenter prospective studies are warranted before clinical implementation.
dc.description.sponsorshipThis Project was supported by Istanbul University Scientific Research Projects Coordination Unit with project number TOA-2020 35780. In the design of the study, the funding body has no role in the manuscript’s preparation, data collection, analysis, and interpretation. Bu proje, İstanbul Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi tarafından TOA-2020 35780 proje numarasıyla desteklenmiştir. Çalışmanın tasarımında, fon sağlayan kuruluşun makalenin hazırlanması, veri toplama, analiz ve yorumlanmasında hiçbir rolü yoktur.
dc.identifier.citationŞükrüoğlu Erdoğan, Ö., Kılıç Erciyas, S., Çelik Demirbaş, B., Dinç, A., Ünal, E., Güngör Uğurlucan, F., Akdeniz Ödemiş, D., Pasin, Ö., Saip, P. M., Yazıcı, H., & Tuncer, Ş. B. (2026). Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer. Molecular Biology Reports, 53(1), pp. 1-11. https://doi.org/10.1007/s11033-026-12485-4
dc.identifier.doi10.1007/s11033-026-12485-4
dc.identifier.endpage11
dc.identifier.issn1573-4978
dc.identifier.issn0301-4851
dc.identifier.issue1
dc.identifier.pmidPMID: 42525292
dc.identifier.scopus2-s2.0-105046241183
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1007/s11033-026-12485-4
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1591
dc.identifier.volume53
dc.identifier.wosWOS:001836297200009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorYazıcı, Hülya
dc.institutionauthorid0000-0002-8919-0482
dc.language.isoen
dc.publisherSpringer Nature Link
dc.relation.ispartofMolecular Biology Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGynecology
dc.subjectDNA Methylation
dc.subjectEpigenomics
dc.subjectGene Expression Regulation
dc.titleBlood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text.pdf
Boyut:
1.72 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu